Journals / Acta Orthopaedica et Traumatologica Turcica / 2009 / Cilt: 43 - Sayı: 2

Management of spasticity in children with cerebral palsy

Beyin felçli çocuklarda spastisitenin tedavisi

Pages
81–86
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There is no standardized approach to spasticity management and this paper will discuss the importance of evidence-based treatment of spasticity that is adapted for the individual child.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Management of spasticity is a major challenge to the reha- bilitation team.
📊
Key Findings & Data:There has been an increased use of intrathecal baclofen in the management of refractory tone.
💡
Conclusion & Impact:There is no standardized approach to spasticity management and this paper will discuss the importance of evidence-based treatment of spasticity that is adapted for the individual child.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Botulinum toksin · tip A · Beyin felci

Abstract

Management of spasticity is a major challenge to the reha- bilitation team. The initial management has centered on the elimination of externally exacerbating causes, physical ther- apy, splinting and casting. Medical management has centered on anti-spasticity medication use, but more recently focal treatment methods including phenol blocks and botulinum toxin have been utilized. There has been an increased use of intrathecal baclofen in the management of refractory tone. Dorsal rhizotomy has been advocated for a selective population of children with spasticity. There is no standardized approach to spasticity management and this paper will discuss the importance of evidence-based treatment of spasticity that is adapted for the individual child.

Özet

Spastisitenin tedavisi rehabilitasyon ekibi için zorlu bir iştir. Başlangıç tedavisi, ağırlaştırıcı dış nedenlerin ortadan kaldırılması, fizik tedavi, atel ve alçılama üzerine yoğunlaşmıştır. Medikal tedavide ise ağırlık spastisiteye karşı ilaç tedavisindedir; ancak, son zamanlarda fenol blokları ve botulinum toksini gibi fokal tedavi yöntemlerinden de yararlanılmaktadır. İlaçlara dirençli tonusun tedavisinde intratekal baklofen kullanımı giderek yaygınlaşmaktadır. Spastik çocukların seçilmiş bir kısmında dorsal rizotomi uygulaması da savunulan yöntemlerden biridir. Spastisitenin tedavisinde standartlaşmış bir yaklaşım bulunmamaktadır. Bu yazıda spastisitede çocuğa özel ve kanıta dayalı tedavinin önemi vurgulanmıştır.

🔖

Cite This Article

MATTHEWS, D. J., BALABAN, B. (2009). Management of spasticity in children with cerebral palsy. Acta Orthopaedica et Traumatologica Turcica, Cilt: 43 - Sayı: 2, 81–86. https://ajindex.com/articles/354449

References (18)

  1. Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N, Dan B, et al. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol 2005;47:571-6
  2. Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW; Task Force on Childhood Motor Disorders. Classification and definition of disorders causing hyperto- nia in childhood. Pediatrics 2003;111:e89-97
  3. Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disorder of motor control. Chicago: Year Book Medical Publishers; 1980. p. 485-94
  4. Massagli TL. Spasticity and its management in children. Phys Med Rehabil Clin N Am 1991;2:867-89
  5. Katz RT. Management of spastic hypertonia after stroke. J Neurol Rehabil 1991;5(Suppl 1):S5-S12
  6. Krach LE. Pharmacotherapy of spasticity: oral medications and intrathecal baclofen. J Child Neurol 2001;16:31-6
  7. Edgar TS. Oral pharmacotherapy of childhood movement disorders. J Child Neurol 2003;18 Suppl 1:S40-9
  8. Milla PJ, Jackson AD. A controlled trial of baclofen in children with cerebral palsy. J Int Med Res 1977;5:398-404
  9. McKinlay I, Hyde E, Gordon N. Baclofen: a team approach to drug evaluation of spasticity in childhood. Scott Med J 1980;S26-8
  10. Gracies JM, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part I: Local treatments. Muscle Nerve Suppl 1997;6:S61-91
  11. Nance PW, Young RR. Antispasticity medications. Phys Med Rehabil Clin N Am 1999;10:337-55
  12. Badell A. The effects of medications that reduce spasticity in the management of spastic cerebral palsy. J Neuro Rehab 1991;5(Suppl 1):S13-S14
  13. Nance P, Meythaler JM. Spasticity management. In: Braddom RL, editor. Physical medicine and rehabilitation, 3rd ed. Philadelphia: Saunders Elsevier; 2006. p. 651-66
  14. Halpern D, Meelhuysen FE. Phenol motor point block in the management of muscular hypertonia. Arch Phys Med Rehabil 1966;47:659-64
  15. Sung DH, Han TR, Park WH, Je Bang H, Kim JM, Chung SH, et al. Phenol block of peripheral nerve conduction: Titrating for optimum effect. Arch Phys Med Rehabil 2001; 82:671-6
  16. Easton JK, Ozel T, Halpern D. Intramuscular neurolysis for spasticity in children. Arch Phys Med Rehabil 1979; 60:155-8
  17. Halpern D, Meelhuysen FE. Duration of relaxation after intramuscular neurolysis with phenol. JAMA 1967;200: 1152-4
  18. Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 19